Conference Coverage
Trending on Modern Retina
1
The gene therapy shift: A closer look at the science powering next-generation retinal treatments
2
Understanding fluid fluctuation in retinal disorders
3
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
4
Evaluating Progressive Multifocal Geographic Atrophy in an Asymptomatic 81-Year-Old Male
5
Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
Latest News
Advertisement
Shorts
0:37
Andreas Pollreisz, MD, encourages taking a second look with OCT-A
3 months ago
by
Andreas Pollreisz, MD(+1 more)
0:43
Sofia Androudi on retinal disorders mimicking inherited retinal diseases
3 months ago
by
Sofia Androudi, MD(+1 more)
0:43
Elon van Dijk on central serous chorioretinopathy
3 months ago
by
Elon van Dijk(+1 more)
0:50
Timothy Lai discusses the SALWEEN 1-year data
3 months ago
by
Timothy Lai(+2 more)
0:37
Giuseppe Querques, MD, PhD, sheds light on two challenging pathophysiologies at EURETINA
3 months ago
by
Giuseppe Querques, MD, PhD(+1 more)
0:49
Why the current staging for diabetic eye disease is obsolete
3 months ago
by
Stela Vujosevic, MD, PhD, FEBO(+2 more)
Podcasts
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice.
The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD
In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists considering this approach.
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
Behind the scenes of building impactful educational platforms in retina care
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
In the debut episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD, about PYK-2101, a biodegradable retinal sealant designed to replace gas and oil tamponades.
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
John Kitchens, MD, and Diana Do, MD, delve into the PHOTON trial results and their significance for treating patients with diabetic macular edema in clinical settings.
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
Join John Kitchens, MD, and David Brown, MD, as they explore the PULSAR study results and their impact on managing neovascular age-related macular degeneration in your practice.
Integrating AI to manage DR in a primary care setting
Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.
What to expect from virtual AAO 2020
American Academy of Ophthalmology (AAO) President Anne L. Coleman, MD, PhD, offers a preview of what attendees can look forward to from the academy's 2020 virtual annual meeting — kicking off Nov. 13-15.
Spotlighting telemedicine in the year of a pandemic
In this EyePod episode, Ranya Habash, MD, of Bascom Palmer Eye Institute, University of Miami, speaks on the expansion of telemedicine in ophthalmology amid the pandemic and why the future of telemedicine requires a new way of thinking.
Putting in practice retina innovations amid a pandemic
S.K. Steven Houston III, MD, shares how his practice has put to use recent retina innovations and adapted to accommodate the ever-changing operating room spacing and set-up in the current COVID-19 environment.
Videos
Modern Retina Digital Edition
Gene therapy revolutionizes retinal disease treatment, offering long-lasting solutions and reducing the need for frequent injections in patients with nAMD.
nAMD treatment options may offer positive outcomes to patients by reducing fluid fluctuations associated with poorer outcomes.
Ophthalmology advances with AI diagnostics and pediatric trauma insights, merging technology and compassion to enhance patient care and outcomes.
Revisiting a classic tool that still gets you out of a jam works best when you understand its powers and limitations.
Reliable visualization tools, especially those indicated for ocular use, are crucial for success.
A look at podium presentations on GA research at ASRS 2025.
Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes.
The role of anesthetics in streamlining efficiency and elevating patient care.
Patients weigh in on the value of provider communication.
Continuing Medical Education
Advertisement
All News
Advertisement
nAMD treatment options may offer positive outcomes to patients by reducing fluid fluctuations associated with poorer outcomes.
Ophthalmology advances with AI diagnostics and pediatric trauma insights, merging technology and compassion to enhance patient care and outcomes.
Choroidal dysfunction plays a crucial role in retinal diseases, highlighting its potential as a therapeutic target and the need for innovative treatments.
Dr. Sharon Fekrat presented a retrospective analysis assessing how antiplatelet and anticoagulant therapy relates to hemorrhage characteristics and outcomes.
Sharon Fekrat discusses the complexities of antithrombotic use in wet AMD, highlighting the need for individualized treatment and future guideline development.
Remote monitoring of age-related macular degeneration enhances patient care, reduces treatment burden, and leverages AI for personalized management.
Prof Dr Rajvardhan Azad explains how unified guidelines, AI-driven tools, and cross-disciplinary collaboration could transform outcomes for premature infants.
Priyanka Sanghi, BSc, MSc, MBBS, highlights how fundus autofluorescence and optical coherence tomography may help uncover long-term retinal footprints invisible to standard examination.
Innovative multimodal deep learning models enhance non-invasive chronic kidney disease screening by integrating retinal images and urine dipstick data for improved accuracy.
Advertisement
Dr. Melissa Yuan discusses the impact of weight and postmenstrual age on foveal maturation in preterm infants, highlighting critical insights for neonatal care.
The Portal extension trial reveals that the Port Delivery System significantly improves vision in AMD patients, showcasing long-term efficacy and durability.
New treatments show promise in preventing fibrosis in neovascular AMD, addressing a critical need for improved visual outcomes in patients.
Dr. J. Peter Campbell discusses the technologies shaping retinopathy of prematurity detection, clinical integration, and global implementation.
To help with education and awareness, Prevent Blindness is providing free, expert-approved educational resources on GA.
The company noted that this approval marks Celltrion's first Health Canada-approved biologic product in ophthalmology.
AAO 2025 highlights groundbreaking advancements in retinal disease treatments, showcasing senolytics, optogenetics, and personalized therapies for improved patient outcomes.
AAO 2025 revealed that true-color widefield imaging, AI-powered home OCT, and refined FAERS analyses are collectively transforming retinal diagnostics into a more precise, continuous, and safety-aware system.
According to the company, this is the first and only single-use kit on the market that includes the diagnostic lens.
Both therapeutics will leverage AGC Biologics’ BravoAAV suspension platform and use an innovative dual AAV vector approach, which splits the therapeutic gene into 2 halves.
EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for improved patient outcomes.
The two meetings will be held concurrently from December 4-7 in Florence, Italy.
For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice.
Chhablani discusses key findings on retinal vasculitis from the FAERS database, highlighting trends and safety in intravitreal treatments.
CoTx-10 is intended for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
RUSH2A is an ongoing natural history study for patients with mutations in the USH2A gene causing Usher syndrome type 2A or nonsyndromic retinitis pigmentosa (RP).
Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and potentially blindness.
Kenneth C. Fan, MD, discusses promising visual improvements from MCO-010 therapy for Stargardt disease at AAO 2025, highlighting future treatment potential.
Anat Loewenstein, MD, discusses the transformative impact of home OCT and AI on monitoring retinal diseases at AAO 2025.
In the study, authors investigated the natural history of GA lesion incidence rates and analyzed potential risk factors for faster incidence of GA lesions.
Advertisement
Advertisement
